
Please try another search
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Name | Age | Since | Title |
---|---|---|---|
Martin J. Murphy | - | - | Independent Non-executive Director |
Zhi Hong | 59 | 2018 | Co-founder, Executive Chairman of the Board & CEO |
Taiyin Yang | 69 | 2022 | Independent Non-Executive Director |
Gregg Huber Alton | 57 | - | Independent Non-executive Director |
Hui Tang | 63 | - | Independent Non-executive Director |
Yiu Wa Tsui | 74 | - | Independent Non-executive Director |
Ankang Li | 46 | 2021 | Chief Financial & Strategy Officer, Joint Secretary and Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review